Background and objective Recent research has highlighted the fundamental role of
sarcopenia, characterized by loss of skeletal muscle mass and strength, with a risk of poor …

Background: Weight loss is frequently reported in patients with idiopathic pulmonary fibrosis
(IPF) and may be associated with worse outcomes in these patients. Objective: The aim of …

In idiopathic pulmonary fibrosis (IPF), several factors may have a negative impact on the
nutritional status, including an increased respiratory muscles load, release of inflammation …

Background Nintedanib is an approved therapy for idiopathic pulmonary fibrosis (IPF). Some
patients treated with nintedanib experience weight loss. Exploratory data suggest that low …

Introduction Identification of clinical characteristics associated with prognosis for idiopathic
pulmonary fibrosis (IPF) may help to guide management decisions. This analysis utilized …

Background and objective Detailed body composition, such as fat‐free mass, has not been
examined in idiopathic pulmonary fibrosis (IPF). We investigated whether the fat‐free mass …

Association between body mass index (BMI) and prognosis in patients with idiopathic
pulmonary fibrosis (IPF) remains uncertain. We investigated the association between BMI …

The identification of novel prognostic biomarkers might enhance individualized
management strategies in patients with idiopathic pulmonary fibrosis (IPF). Although several …

Background Lower body mass index (BMI) and weight loss have been associated with
worse outcomes in some studies in patients with pulmonary fibrosis. We analyzed outcomes …

Background Mortality risk assessment in interstitial lung disease (ILD) is challenging. Our
objective was to determine the prognostic significance of BMI and change in weight in the …